Enzyvant focuses on innovative treatments, science, and technology to address patient needs in psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapy. Self-described as an innovation growth engine, the company aims to improve patient outcomes.

Enzyvant

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Metric
Company Name	Enzyvant	Sarepta Therapeutics, Inc.
Symbol		SRPT
MSH ID	COM:ENZYVANT	COM:SAREPTA
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Post-IPO Equity
Employee Count		1.31K
Website	enzyvant.com	sarepta.com
LinkedIn
Founders

Metric
Market Cap		14.11B
Enterprise Value
Monthly Web Traffic		12.98K
Web Traffic Growth		-0.26
Valuation
Raised Capital		5.96M

Metric
Revenue		1.24B
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.09B
EBITDA		-267.82M
Operating Income		-267.82M
Net Income		-535.98M
EPS		-5.80
Diluted EPS		-5.80
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.88
Operating Profit Margin		0.03
EBITDA Margin		-0.22
Net Profit Margin		0.03
Return on Equity		0.05
Return on Assets		0.01
Return on Capital Employed		0.01

COM:ENZYVANT

Enzyvant

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-16.13
P/B Ratio		14.58
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		11.03
EV Multiple		207.35

Metric
Days Sales Outstanding		117.02
Days Payables Outstanding		234.37
Days Inventory Outstanding		958.33
Operating Cycle		1.05K
Cash Conversion Cycle		841.56
Asset Turnover		0.44

Metric
Operating Cash Flow		-500.99M
Free Cash Flow		-588.34M
Cash Flow to Debt		-0.32
Operating Cash Flow/Sales		-0.26
Free Cash Flow Yield		-0.05

Metric
Cash & Equivalents		428.43M
Accounts Receivable		-185.70M
Inventory		322.86M
Goodwill
Debt to Capitalization		0.59
Debt to Assets		0.54
Current Ratio		5.44
Quick Ratio		3.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.17
R&D to Revenue		0.81
SG&A to Revenue		0.43